Monday, 20 May 2024
  
Login

Australia's most trusted
source of pharma news

Monday, 20 May 2024
Listen to this story 
News

AZ crunches the numbers on CKD

Posted 7 May 2024 AM

A surge in chronic kidney disease (CKD) in Australia will cost the economy billions and increase associated environmental costs, according to research by AstraZeneca.

The pharma, which sponsors SGLT2 inhibitor Forxiga in Australia, which is indicated for CKD, presented the Multidimensional burden of chronic kidney disease in eight countries: Insights from the IMPACT CKD study at the 2024 ISN World Congress of Nephrology. The research was conducted by 12 international scientists, including Professor Stephen Chadban from the Royal Prince Alfred Hospital Department of Renal Medicine.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (22)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (30)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.